Overview

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Phase:
PHASE3
Details
Lead Sponsor:
Insmed Incorporated